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 Abstract 
Diabetic eye disease is one of the fastest growing causes of preventable blindness. With 
the advent of anti-VEGF (vascular endothelial growth factor) therapies, it has become 
increasingly important to detect center-involved diabetic macular edema (ci-DME). However, 
center-involved diabetic macular edema is diagnosed using optical coherence tomography 
(OCT), which is not generally available at screening sites because of cost and workflow 
constraints. Instead, screening programs rely on the detection of hard exudates in color fundus 
photographs as a proxy for DME, often resulting in high false positive or false negative calls. To 
improve the accuracy of DME screening and enable more timely referrals for these patients, we 
trained a deep learning model to use color fundus photographs to predict ci-DME. Our model 
had an ROC-AUC of 0.89 (95% CI: 0.87-0.91), which corresponds to a sensitivity of 85% at a 
specificity of 80%. In comparison, three retinal specialists had similar sensitivities (82-85%), but 
only half the specificity (45-50%, p<0.001 for each comparison with model). The positive 
predictive value (PPV) of the model was 61% (95% CI: 56-66%), approximately double the 
36-38% by the retinal specialists.  In addition to predicting ci-DME, our model was able to detect 
the presence of intraretinal fluid with an AUC of 0.81 (95% CI: 0.81-0.86) and subretinal fluid 
with an AUC of 0.88 (95% CI: 0.85-0.91). The ability of deep learning algorithms to make 
clinically relevant predictions that generally require sophisticated 3D-imaging equipment from 
simple 2D images has broad relevance to many other applications in medical imaging. 
 
  
 
 Introduction 
Diabetic macular edema (DME) is a late stage of diabetic eye disease that is characterized 
by retinal thickening in the macula, often accompanied by hard exudate deposition, and resultant 
vision loss. It is one of the most common reasons for referrals to diabetic eye clinics and affects 
3-33% of patients with diabetes.​1​  The wide range of prevalences reflects the varied bases for 
defining the condition as well as the varied composition of the populations studied. Currently, 
the first-line treatment for DME is anti-vascular endothelial growth factor (anti-VEGF) agents.​2–4 
To determine eligibility for anti-VEGF treatment of DME, most of the major clinical trials 
measured macular thickening using optical coherence tomography (OCT), and initiated treatment 
if a patient met the criteria for a particular type of DME.​5,6​ This type of DME is now commonly 
called center-involved DME (ci-DME) in clinical practice. As such, findings on OCT along with 
impaired visual acuity has become a widely-accepted standard of care for determining DME 
treatment.​7 
However, despite improvements in therapy, the detection of ci-DME remains a challenge 
because adding OCTs to the screening process is too costly and logistically difficult to 
implement widely. Globally, there are 425 million patients with diabetes​8​ and most clinical 
guidelines recommend that all of them are screened annually.​9​ Currently, selection of patients 
who may meet treatment criteria is performed during these screenings, which typically utilize 
monoscopic fundus images. These images are then evaluated for the presence of hard exudates 
within one optic disc diameter of the center of the macula, a proxy for ci-DME.​10​ However, this 
proxy was developed based on an older standard of care, and some studies have shown that hard 
exudates have both poor positive predictive value and poor sensitivity for ci-DME. MacKenzie ​et 
 
 al.​ reported that only 42% of patients with hard exudates were found to have DME on OCT,​11 
and Wang ​et al.​ reported that a third of patient-eyes with DME detected on OCTs lacked features 
such as hard exudates on monoscopic fundus photographs.​12​ Wong ​et al​ reported a false positive 
rate of 86.6% for DME screening with existing strategies.​13​ As such, the potential of DR 
screening and timely referral for DME is handicapped by an inability to reliably detect ci-DME 
via human-evaluation of fundus photographs alone. 
A potential solution lies in the use of deep learning algorithms, which have been applied 
to a variety of medical image classification tasks,​14–16​ including for retinal imaging.​17–20 
Encouragingly, in addition to achieving expert-level performance for grading fundus images, 
deep learning algorithms are able to make predictions for which the underlying association with 
fundus images were previously unknown, such as cardiovascular risk factors​21​ and refractive 
error.​22​ Thus, we hypothesized that deep learning could be leveraged to directly predict the 
OCT-derived DME grade using monoscopic fundus photographs. 
 
Results 
To leverage deep learning as a potential solution to reliably detect ci-DME, we propose 
developing models on fundus photographs, but using ci-DME diagnoses derived from expert 
inspection of OCT (Figure 1). To train and validate the model, cases were gathered 
retrospectively from the Rajavithi Hospital in Bangkok, Thailand.  Because these cases were 
gathered from those referred into the retina clinic for further evaluation, the disease distribution 
is consistent with a population presenting to specialty clinics, and enriched for more severe 
disease as compared to a DR screening population. Details of the development and clinical 
 
 validation datasets are presented in Table 1. The development dataset consisted of 6,039 images 
from 4,035 patients and the primary clinical validation dataset consisted of 1033 images from 
697 patients. For some patients, only one eye was included because the fellow eye fell under the 
exclusion criteria. ci-DME was conservatively defined as center point thickness >= 250 μm 
measured via manual caliper measurements excluding the retinal pigment epithelium.​23,24​ We 
trained a model using this development dataset to predict ci-DME using fundus photographs as 
input. 
Our model showed a higher performance in detecting cases with and without ci-DME 
from monoscopic fundus images compared to manual grading of fundus images (Table 2 and 
Figure 2). For ci-DME, the model had a sensitivity of 85% at a specificity of 80%. Three retinal 
specialists had sensitivities ranging from 82-85% at specificities ranging from 45-50%. The 
performance improvements held true even if other common criteria for calling DME for 
monoscopic images were used (Figure S1), such as changing the definition of DME based on the 
location of the hard exudates. ​Additional analyses were also performed at other thickness 
thresholds for ci-DME at center point thickness >=280 μm and >=300 μm, which showed similar 
or better results compared to the conservative >=250 μm cut off point without model retraining 
(Figure S2). ​When compared to manual grading, our model had a 30-35% absolute higher 
specificity at the same sensitivity (p<0.001 for comparison with each retinal specialist). When 
matched to have the same specificity, the model had a 11-14% absolute higher sensitivity (96% 
vs. 82-85%, p<0.001 for all comparisons).  
In addition to predicting ci-DME, our model was able to predict presence of intraretinal 
and subretinal fluid. Our model had an AUC of 0.81 (95% CI: 0.81-0.86) for  detecting 
 
 intraretinal fluid presence and an AUC of 0.88 (95% CI: 0.85-0.91) for subretinal fluid presence 
(Figure 3). 
In addition to the primary clinical validation dataset, the model was also applied to a 
secondary validation dataset, EyePACS-DME, to examine the model’s generalizability. This 
dataset consists of 990 images with moderate, severe non-proliferative DR or proliferative DR, a 
subset of data previously gathered during another DME study.​25​ The images were gathered using 
a Canon CR-DGi camera and OCTs were taken with a Optovue iVue machine from a U.S.-based 
population (see methods). There are some notable differences in this dataset in comparison to the 
primary validation dataset, particularly in terms of defining and measuring ci-DME based on 
central subfield thickness and incorporation of inclusion/exclusion criteria (Table S2). Based on 
this different definition and inclusion criteria, the number of ci-DME cases in the secondary 
validation set was 7.8% compared to 27.2% in the primary clinical validation set. Thus, the 
model performance on the datasets cannot be compared directly in terms of absolute values 
(especially for metrics like PPV which depend a lot on the priori distribution). However, relative 
comparisons between the model and graders (in this instance EyePACS certified graders) can be 
drawn (Figure 4 and Table 3). Similar to the results of the primary validation, our model had a 
positive predictive value (PPV) roughly twice that of manual grading using hard exudates as 
proxy (35% [95% CI: 27%-44%] vs 18% [95% CI: 13%-23%]) and similar NPV (96% [95% CI: 
95%-98%] vs 95% [95% CI: 94%-97%]). This translated to a similar sensitivity (57% [95% CI: 
47%-69%] vs 55% [43%-66%]) but higher specificity (91% [95% CI: 89%-93%] vs 79% [95% 
CI: 76%-82%]).  
 
 Subsampling experiments, where new models were trained using titrated fractions of the 
dataset, showed that model performance continued to increase with larger training sets (see 
Figure 3 - where AUC increases with sample size). These results suggest that the accuracy of this 
prediction will likely continue to increase with dataset sizes larger than that in this study.  
Figure 5 presents an analysis of the areas in the fundus image relevant for the model. 
When the model was trained on cropped fundus images containing only 0.25 optic disc diameter 
around the fovea (blue line), it achieved an AUC of 0.75.  When it had access to 1.0 optic disc 
diameter around the fovea, the model achieved an AUC greater than 0.85, comparable with its 
performance on the full fundus image. However, the model trained on the region around the 
optic disc needed to see a lot more context (2.5 optic disc diameter) around the optic disc center 
to achieve an AUC exceeding 0.8. Based on these results, we believe the model primarily utilizes 
the area around the fovea to make ci-DME predictions. 
 
 
Discussion 
While the potential of deep learning to make novel predictions has been reported in 
literature, ​21,22​ this study is among the first robust examples of a model far exceeding expert 
performance for a task with high clinical relevance and potentially important implications for 
screening programs worldwide. The resultant model performed significantly better than retinal 
specialists for detecting ci-DME from fundus images in two datasets from very different 
populations. DME is the major cause of visual loss from DR. Prior to the use of anti-VEGF 
injections, the Early Treatment of Diabetic Retinopathy Study (ETDRS) showed that treatment 
 
 of a subtype of DME with focal laser photocoagulation decreased the chance of vision loss.​26 
Today, with anti-VEGF injections, the treatment of ci-DME can ​improve ​ vision by 
approximately 10-13 letters as measured using the ETDRS visual acuity chart.​5​ Anti-VEGF 
injections are now largely considered the gold standard of care with evidence that shows that 
delaying treatment of DME could lead to suboptimal visual improvement.​27​ However, the current 
grading guidelines in screening programs were developed before the advent of anti-VEGF 
therapy and are not specifically designed for detecting ci-DME. The development of models that 
can better detect ci-DME in DR screening programs using existing equipment (color fundus 
cameras) is both scientifically interesting and clinically impactful.  
For DR screening in particular, our model may lead to fewer false negatives for DME. 
Decreasing missed referrals for patients with ci-DME presenting with no hard exudates is a clear 
advantage of such a system. Visual acuity alone is not enough to rule out ci-DME as baseline 
characteristics from some well-known cohorts suggest that a substantial percentage of eyes with 
ci-DME still have good vision. ​28,29​ In addition, decreasing false positives is also important in 
resource-constrained settings. While many screening programs recommend closer follow up for 
patients with mild or worse DR, the urgency of follow up varies widely, especially in low 
resource settings. Per international guidelines (International Council of Ophthalmology 
Guidelines, American Academy of Ophthalmology), for patients with mild DR and no macular 
edema, referral is not always required and patients can be rescreened in 1-2 years in 
low/intermediate resource settings and 6-12 months in high resource settings. However, patients 
with suspected ci-DME need to be referred within a month. For patients with moderate 
nonproliferative DR and no macular edema, follow up changes from 6-12 months in 
 
 low/intermediate resource or 3-6 months in high resource settings to 1 month (all resource 
settings) when there is ci-DME.​30,31​ In this study, roughly 88% of the moderate non-proliferative 
patients from the EyePACS-DME dataset and 77% of those from the Thailand dataset who 
would have been referred urgently (and unnecessarily) using a hard exudate based referral 
criterion did not have ci-DME. Higher urgency referral of patients with moderate 
non-proliferative DR without DME (but presenting hard exudates) can be a major issue where 
there are limited resources for evaluation and treatment.  
Furthermore, the center point thickness distribution of the false positive and false 
negative instances is better for the model when compared to retina specialists (Figure S3). For 
the model, 28% of the false positives have thickness > 225 microns and 35% of the false 
negatives have thickness < 275 microns. In comparison, for retina specialists, only 20% of the 
false positives have thickness > 225 microns and 17% of the false negatives have thickness < 
275 microns. This shows that a significantly larger fraction of the model false positives and 
negatives are borderline cases as compared to retina specialists. In addition, the new model 
seems to be able to detect the presence of intraretinal and/or subretinal fluid, both of which merit 
closer monitoring and possibly treatment.​32​ The ability to detect these pathologies is also novel 
since this is not a task that doctors can do accurately from fundus images.  
Although the performance of the models on the secondary dataset is lower than that of 
the models on the primary dataset, the performance of the human graders on the secondary 
dataset is proportionally lower as well. From the primary to secondary dataset, PPV of the model 
decreased from 61% to 35% whereas of the graders decreased from 37% to 18%; sensitivity of 
the model decreased from 85% to 57% whereas of the graders decreased from 84% to 55%. 
 
 However, NPV of the model increased from 93% to 96% whereas of the graders increased from 
88% to 95%; specificity of the model increased from 80% to 91% whereas of the graders 
increased from 47% to 79%. These results reflect the inherent differences between the two 
datasets but still support the better performance of the model over graders on both datasets. 
While the models trained in this study are more accurate than manual grading, there is capacity 
for improvement. Given the results of the subsampling experiments, it is likely that the accuracy 
of the model may continue to increase with larger dataset sizes.  
From a scientific point of view, this work demonstrates the potential of deep learning to 
enable diagnostics from inexpensive hardware, that was only previously possible from expensive 
equipment. It also lays the groundwork for understanding how the model makes these 
predictions. The explanation technique employed in this study indicated that the region around 
the fovea is more relevant than the region near the optic disc for DME prediction from fundus 
images. Future work could involve diving deeper into the features around this area that is picked 
up by deep learning but overlooked by retinal specialists. 
In a small non-randomized study, Scott ​et al.​33​ showed a beneficial effect of focal and 
grid laser for eyes without central involvement that meet an older criteria for treatment known as 
clinically significant macular edema, similar to the initial ETDRS findings. These patients need 
to be referred from a DR screening program for closer follow up. Our model does not evaluate 
such cases. To address this, one would include stereoscopic imaging in addition to OCT as 
ground truth to train model(s) to specifically identify these cases. While there is some evidence 
of generalization to a secondary dataset, the confidence intervals are wide and the criteria for 
ci-DME for the EyePACS-DME dataset were different from those of the Thailand dataset. Some 
 
 of the performance metrics reported in this study such as positive predictive value (PPV) and 
negative predictive value (NPV) are relevant only to populations whose severity distribution is 
similar to that of this study (e.g. patients referred to specialist clinics). Further studies should 
validate the model on additional larger datasets from other settings, including screening settings 
from other regions or geographies. Future studies should also include better standardization for 
ci-DME and inclusion/exclusion criteria as well as sub-analysis of patients who were treated for 
DME. Moreover, additional data diversity such as the use of ci-DME labels derived from other 
OCT devices by other manufacturers should be included in future work. Since the model was 
trained using treatment-naive fundus images, training on multiple images per eye (including with 
stereo pairs), and on eyes that have been treated for DME in the past could lead to better model 
performance. While our cropping experiments (Figure 5) shows that the model looks at the 
region around the fovea for predicting ci-DME, future work could further explore interpretability 
of the model ​33​. Lastly, future work could also include health economic analysis to study the 
cost-effectiveness of such an approach. 
Nevertheless, this study demonstrates that deep learning can be leveraged to identify the 
presence of ci-DME using the cheaper and more-widely available fundus photograph, at an 
accuracy exceeding that of manual grading using expert-derived rules. Similar approaches could 
be particularly valuable for other medical images, such as using radiographs or low-dose 
computed tomography to detect conditions that would otherwise require more expensive imaging 
techniques that expose patients to higher radiation doses. Importantly, we also use crops around 
the fovea and optic disc to explain how the model is making these predictions, lending 
confidence that the predictions will generalize to new unseen datasets. 
 
  
Methods 
This study was approved by the Ethics Committees or ​Institutional Review Boards ​of 
hospitals or health centers where retinal images of patients with diabetes were used in this study, 
including the Rajavithi Hospital (Bangkok, Thailand), Alameda Health Service (Alameda, CA, 
USA), and the U ​niversity of California, Berkeley (Berkeley, CA, USA)​. Patients gave informed 
consent allowing their retinal images to be used. This study was registered in the Thai Clinical 
Trials Registry, Reg​istration Number TCTR20180818002.  
 
Datasets 
For algorithm development, 7,072 images were gathered retrospectively from diabetic 
patients presenting to the retina clinic at Rajavithi Hospital in Bangkok, Thailand from January 
2010-February 2018. ​Only cases that were naive to treatment (both intravitreal injections and 
lasers) were included. Cases where macular lesions may have hyporeflective spaces on OCT, 
such as Macular Telangiectasia Type 2, may interfere with the diagnosis of DME, such as 
idiopathic epimacular membrane, macular edema from other causes, or proliferative DR with 
neovascular membrane affecting the macula, were excluded from analysis.  
Retinal fundus images were obtained using ​Kowa color fundus camera (VX-10 model, 
Kowa, Aichi, Japan)​. A single macula-centered color fundus photograph per eye was used in the 
study. If available, imaging from both eyes were included. OCTs were obtained using the 
Heidelberg Spectralis OCT (Heidelberg Engineering GmbH, Germany) and thickness 
measurements were measured manually (see below for measurement procedures).  
 
 Of the 7,072 images in the dataset, 6,039 were used for development while 1,033 were 
set aside for clinical validation. All images from a patient was present in either in development 
or validation sets, but not both. Fundus photographs in the validation set were manually graded 
by U.S. board-certified retinal specialists to assess the presence and location of hard exudates 
(yes, no, ungradable, within 500 ​μm ​ or 1 disc diameter or 2 disc diameter from the center of the 
macula) and focal laser scars. In addition, retinal specialists provided their best clinical 
judgement of the presence of DME that took into account all the pathology present in the image. 
To study generalizability of the model, the algorithm was applied to another dataset, 
EyePACS-DME, which is a subset of data that had been previously gathered for another DME 
study. ​25​ This dataset consisted of 990 macula-centered images from 554 patients with at least 
moderate DR based on grading by certified EyePACS graders (to roughly match the population 
of those who would be presenting to a retina clinic). No other exclusion criteria were applied to 
this dataset (e.g. exclusion of epiretinal membrane, etc). Fundus images were taken with a Canon 
CR-DGi camera (Ōta, Tokyo, Japan) and OCTs were taken with a Optovue iVue machine 
(Fremont, CA, USA). 
 
Measurement and assessment of OCT scans 
For the Thailand dataset, central subfield thickness, the value representing the thickness 
of the center of the macula in clinical trials for DME,​24​ was not available in all eyes in the 
developmental dataset; therefore center point thickness, which was found to have high 
correlation with the central subfield thickness,​23​ was measured for each eye to represent the 
thickness of the center of the macula. 
 
 The center point thickness of an eye of a patient was manually measured on the axis of 
the OCT scan where there was a slight elevation of the ellipsoid zone and the gap between the 
photoreceptor layer outer segment tip and the ellipsoid zone was the widest, indicating the center 
of the fovea where the cone cell density is the highest. Manual measurement was conducted 
using the straight-line measurement vector available with the Spectralis Eye Explorer software. 
The vector was put perpendicular to the highly reflective band of retinal pigment epithelium with 
one side of the vector rested on the highly reflective line of cone outer segment tip and the other 
side on the internal limiting membrane. Retinal pigment epithelium thickness was not included in 
this measurement. Intraretinal fluid was defined as present when a cystoid space of 
hypo-reflectivity was found within 500 ​μm ​ of the foveal center of any OCT scans of a patient. 
Subretinal fluid was defined as present when a space of hypo-reflectivity was found between the 
retina and retinal pigment epithelium within 500 ​μm ​ of the foveal center of any OCT scans of a 
patient. 
The measurement of center point thickness and the assessment of presence of intraretinal 
fluid and subretinal fluid were conducted by 2 medical doctors experienced in clinical research 
and supervised by retinal specialists. 5% of patients were randomly selected to confirm all three 
measurements by a retinal specialist with 20 years of post-certification experience. 
Eyes were divided into cases of no ci-DME and ci-DME. ci-DME was conservatively 
defined as eyes with >= 250 μm center point thickness, excluding the retinal pigment epithelium 
based upon manual measurement.​23,24​ In addition to ci-DME, we also trained the model in a 
multi-task fashion to predict subretinal fluid and intraretinal fluid (details below). While cases 
 
 with subretinal fluid and intraretinal fluid were not strictly included in the criteria in the clinical 
anti-VEGF trials for DME, referral for follow-up is warranted for these cases. 
For the EyePACS-DME dataset, the manufacturer’s automated segmentation algorithm 
was used to measure central subfield thickness. A cut off of 300 μm central subfield thickness 
was used as the cut-off point for ci-DME based on machine-specific adjustments.​34​ The presence 
of intraretinal and subretinal fluid were not available in this dataset. 
 
Model 
Our deep learning algorithm for predicting ci-DME was built using the methods 
described by Gulshan ​et al.​,​17​ using the Inception-v3​35​ neural network architecture.  Briefly, we 
used a convolutional neural network​36​ to predict ci- DME (center point thickness >= ​250 μm​), 
subretinal fluid presence and intraretinal fluid presence in a multi-task fashion. The input to the 
neural network was a color fundus photograph, and the output was a real-valued number between 
0 and 1 for each prediction, indicating its confidence. For other hyperparameter and training 
details see Figure S4. 
The parameters of the neural network were determined by training it on the fundus 
images and OCT-derived ci-DME grades in the development dataset. Repeatedly, the model was 
given a fundus image with a known output as determined by a ​grader ​ looking at the patient’s 
corresponding OCT . The model predicted its confidence in the output, gradually adjusting its 
parameters over the course of the training process to become more accurate. Note that the model 
never sees the actual OCT image during training or validation. 
 
 
  
Evaluating the algorithm 
To evaluate the performance of the model, we used the ​receiver operating characteristic 
(ROC) curve and calculated the area under the curve (AUC)​. The performance of the retinal 
specialists was marked by points on this curve indicating their sensitivity and specificity (Figure 
2). The same model was also evaluated at increasing thresholds of thickness for ci-DME, without 
retraining (Figure S2). By choosing an operating point on the ROC curve that makes the model’s 
specificity match that of retinal specialists, we also evaluated the model using Sensitivity, 
Specificity, Positive Predictive Value, Negative Predictive Value, Accuracy and Cohen’s Kappa 
score​37​ (Table 2). 
 
Statistical Analysis 
To assess the statistical significance of these results, we used the non-parametric 
bootstrap procedure: from the validation set of ​N​ patients, sample ​N​ patients with replacement 
and evaluate the model on this sample. By repeating this sampling and evaluation 2,000 times, 
we obtain a distribution of the performance metric (e.g. AUC), and report the 2.5 and 97.5 
percentiles as 95% confidence intervals. For statistical comparisons, the permutation test was 
used with 2,000 random permutations.​38 
 
Model Explanation 
We performed two experiments to determine which regions in a fundus image are most 
informative of DME. We focussed on two regions, the macula and the optic disc. First, a group 
 
 comprised of ophthalmologists and optometrists manually marked the fovea and disc for all 
images in the Thailand dataset. We then trained and evaluated our model looking only at the 
region that is within a factor of optic disc diameters around the fovea (or equivalently the optic 
disc) with the rest of the fundus blacked out. We trained and evaluated different models for 
different radii, increasing the area that the model looks at to understand the importance of these 
regions in making the prediction. (Figure 5) 
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 Figures & Tables 
 
 
Characteristics 
Thailand dataset EyePACS-DME 
dataset 
Development 
Set 
Primary Clinical 
Validation Set 
Secondary Clinical 
Validation Set 
Number of Patients 4035 697 554 
Number of Fundus Images 6039 1033 990 
Camera used for Fundus Images Kowa VX-10 Canon CR-DGi 
OCT device used for determining ci-DME Heidelberg Spectralis Optovue iVue 
Age: Mean, years (SD) 55.6 (10.8) 
n​=6038 
55.8 (10.8) 
n​=1033 
62.0 (9.8) 
n​=990 
Gender (% male) 60.8% 
n​=6036 
62.4% 
n​=1031 
50.1% 
n​=990 
Central Retinal Thickness: Mean, μm (SD) 263.8 (146.5) 
n​=6039 
258.4 (132.8) 
n​=1033 
254.4 (56.3) 
n​=990 
ci-DME, Center Point Thickness >= 250um 
in Thailand dataset. Central Subfield 
Thickness >= 300um in the Eyepacs-DME 
dataset 
28.3% 
n​=6039 
27.2% 
n​=1033 
7.8% 
n​=990 
Subretinal Fluid Presence 15.7% 
n​=6039 
15.1% 
n​=1033 
N/A 
Intraretinal Fluid Presence 45.5% 
n​=6039 
46.3% 
n​=1033 
N/A 
 
Table 1​: Baseline characteristics of the development and primary clinical validation datasets. Note that 
the difference between total n and subcategories is missing data (e.g. not all images had age or sex) 
 
 
 
  
Figure 1: ​Illustration of our proposed approach for developing a ci-DME model.​ ​Ground truth for ci-DME 
were derived from a human grader analyzing the OCT for each case. Additionally subretinal fluid and 
intraretinal fluid presence grades were also collected. These ground truth labels and corresponding color 
fundus photos were used for model training. For clinical validation, the trained model takes in a new 
fundus photo and generates a predicted ci-DME grade, predicted subretinal fluid and intraretinal fluid 
presence grades. 
 
 
  
Figure 2:​ Receiver operating characteristic curve of the model with retinal specialists’ grades shown as 
red dots for predicting ci-DME on the primary clinical validation set. All methods (i.e. the model and retinal 
specialists) rendered their grades using monoscopic fundus images only. The ground truth for ci-DME 
was derived using OCT (center point thickness>=250 μm).  
 
  
 
Metric Model Specialist 1 Specialist 2 Specialist 3 
Positive Predictive Value (%), 
95% CI 
61% [56%-66%] 
n​=1033 
37% [33%-40%] 
n​=1004 
36% [33%-40%] 
n​=987 
38% [34%-42%] 
n​=1001 
Negative Predictive Value (%), 
95% CI 
93% [91%-95%] 
n​=1033 
88% [85%-91%] 
n​=1004 
89% [85%-92%] 
n​=987 
88% [84%-91%] 
n​=1001 
Sensitivity (%), 95% CI 85% [80%-89%] 
n​=1033 
84% [80%-89%] 
n​=1004 
85% [80%-89%] 
n​=987 
82% [77%-86%] 
n​=1001 
Specificity (%), 95% CI 80% [77%-82%] 
n​=1033 
45% [41%-48%] 
n​=1004 
45% [41%-48%] 
n​=987 
50% [47%-54%] 
n​=1001 
Accuracy (%), 95% CI 81% [79%-83%] 
n=1033 
56% [52%-59%] 
n=1004 
56% [52%-59%] 
n=987 
59% [56%-62%] 
n=1001 
Cohen's Kappa, 95% CI 0.57 [0.52-0.62] 
n=1033 
0.21 [0.16-0.25] 
n=1004 
0.21 [0.16-0.25] 
n=987 
0.24 [0.19-0.28] 
n=1001 
 
Table 2: ​Performance metrics (PPV, NPV, Sensitivity, Specificity, Accuracy and Cohen's Kappa) of the 
model for predicting ci-DME compared with 3 retinal specialists on the primary clinical validation set. For 
the model we chose an operating point that matched the sensitivity of the retinal specialists to calculate 
the metrics. The performance metrics for the model were calculated on the entire primary clinical 
validation set; for the retinal specialists it was calculated only on the images that they marked as 
gradable. Brackets denote 95% confidence intervals.  
 
 
 
 
  
Figure 3.​ Effect of data size on predicting ci-DME, subretinal fluid and intraretinal fluid presence on the 
primary clinical validation set. A subsampled fraction of 1.0 indicates the entire training dataset. Model 
performance continues to increase with increased data suggesting that the accuracy of the predictions will 
likely improve if the model is trained with more data. 
 
 
 
 
  
 
  
Figure 4: ​Receiver operating characteristic curve of the model with eyepacs graders’ grades shown as a 
red dot for predicting ci-DME on the secondary clinical validation set. All methods (i.e. the model and 
eyepacs graders) rendered their grades using monoscopic fundus images only. The ground truth for 
ci-DME was derived using OCT (central subfield thickness>=300 μm). 
   
 
  
Figure 5: ​Plot​ showing model performance in predicting ci-DME on the primary clinical validation set, as 
measured by AUC when cropped circular images are used to train and validate the model. The blue line 
indicates the performance when cropped circular images of different sizes (radius of multiples of disc 
diameter from 0.05 to 2.5) centered at the fovea are used, while the green line indicates the 
corresponding performance when the crops are centered at the optic disc. (Inset) Image depicting some 
of the regions of different radii (0.05, 0.125, 0.25, 0.5, and 1 disc diameter) around the fovea and optic 
disc​.​ (Bottom panel) Fundus image, followed by the crops extracted by centering at the ​optic disc (green) 
and ​fovea (blue)​, with the extraction radius in multiples of disc diameter indicated in each crop. 
 
Metric Model EyePACS Graders 
Positive Predictive Value (%), 95% CI 35% [27%-44%] 18% [13%-23%] 
Negative Predictive Value (%), 95% CI 96% [95%-98%] 95% [94%-97%] 
Sensitivity (%), 95% CI 57% [47%-69%] 55% [43%-66%] 
Specificity (%), 95% CI 91% [89%-93%] 79% [76%-82%] 
Accuracy (%), 95% CI 88% [86%-91%] 77% [74%-80%] 
Cohen's Kappa, 95% CI 0.38 [0.29-0.47] 0.17 [0.11-0.24] 
 
Table 3: ​Performance metrics (PPV, NPV, Sensitivity, Specificity, Accuracy and Cohen's Kappa) of the 
model for predicting ci-DME compared with eyepacs graders on the secondary clinical validation set 
 
 (n=990). For the model we chose an operating point that matched the sensitivity of the eyepacs graders 
to calculate the metrics. Brackets denote 95% confidence intervals.   
 
  
Supplement 
 
 
Figure S1:​ Receiver operating characteristic curve of the model with retinal specialists’ grades shown as 
red, yellow, and cyan dots for predicting ci-DME using different criteria for manual grading for DME on the 
primary clinical validation set. All methods (i.e. the model and retinal specialists) rendered their grades 
using monoscopic fundus images only. The ground truth was derived using OCT (center point 
thickness>=250 μm).  
 
  
A. CPT>=280 μm 
 
 
  
 
 B. CPT>=300 μm 
 
 
  
 
 C. CPT>=320 μm 
 
 
Figure S2: ​Receiver operating characteristic curve of the model with retinal specialists’ grades shown as 
red dots for predicting ci-DME on the primary clinical validation set. All methods (i.e. the model and retinal 
specialists) rendered their grades using monoscopic fundus images only. The ground truth was derived 
using OCT at different center point thickness cut-offs for the definition of ci-DME. (A) 280 μm, (B) 300 μm, 
and (C) 320 μm. 
 
 
  
 
Figure S3: ​Center point thickness distribution of false positive (top) and false negative (bottom) instances 
for the model (left) and the retina specialists (right). To combine the grades from the three retina 
specialists we considered the case to be positive for ci-DME only if a majority of retina specialists agreed 
it was referable for DME. For the model, we chose an operating point that matched the sensitivity of the 
retina specialists. 
  
 
  
 
 
 
 
 
 
 
 
● Inception-v3 architecture [See​ tf.contrib.slim.nets.inception_v3​]. 
Weights initialized from a checkpoint trained for the Imagenet classification 
task. 
● Input image resolution: 587 × 587 
● Learning rate: 0.001 
● Batch size: 32 
● Weight decay: 4 · 10−5 
● Dropout keep probability: 0.8 
● An Adam optimizer with β1 = 0.9, β2 = 0.999, and ε = 0.1 [see 
tf.train.AdamOptimizer​] 
● Data augmentation (in order): 
1. Random vertical and horizontal reflections [see 
tf.image.random_flip_left_right ​and 
tf.image.random_flip_up_dow​n] 
2. Random brightness changes (with a max delta of 0.114752799273) 
[see the TensorFlow function ​tf​.​image​.​random_brightness​] 
3. Random saturation changes between 0.559727311134 and 
1.27488446236 [see ​tf.image.random_saturation​] 
4. Random hue changes between -0.0251487996429 and 
0.0251487996429 [see ​tf.image.random_hue​] 
5. Random contrast changes between 0.999680697918 and 
1.77048242092 [see ​tf.image.random_contrast​] 
● The model was trained for 2 million steps 
● Model evaluations performed using a running average of parameters, with a 
decay factor of 0.9999 
 
Figure S4: ​Data augmentation and model hyperparameters used for training the model. 
 
 
Metric Model Specialist 1 Specialist 2 Specialist 3 
Positive Predictive Value (%), 
95% CI 
61% [57%-66%] 36% [33%-40%] 37% [33%-41%] 38% [34%-42%] 
Negative Predictive Value (%), 
95% CI 
93% [91%-95%] 
 
88% [85%-92%] 89% [86%-92%] 87% [84%-90%] 
Sensitivity (%), 95% CI 85% [81%-89%] 85% [80%-89%] 86% [82%-90%] 81% [76%-86%] 
 
 Specificity (%), 95% CI 80% [77%-83%] 44% [40%-47%] 44% [40%-48%] 49% [45%-53%] 
Accuracy (%), 95% CI 81% [78%-84%] 55% [52%-58%] 56% [53%-59%] 57% [55%-61%] 
Cohen's Kappa, 95% CI 0.58 [0.52-0.63] 0.20 [0.16-0.24] 0.21 [0.17-0.25] 0.22 [0.18-0.27] 
 
Table S1: ​Performance metrics (PPV, NPV, Sensitivity, Specificity, Accuracy and Cohen's Kappa) of the 
model for predicting ci-DME compared with the 3 retinal specialists, calculated only on the images that all 
3 retinal specialists deemed gradable (n=948). For the model, we chose an operating point that matched 
the sensitivity of the retinal specialists to calculate the metrics.  Brackets denote 95% confidence 
intervals.  
 
 
 Thailand dataset EyePACS-DME dataset 
Patient Population Patients in Thailand presenting 
to a retina clinic of a tertiary 
hospital 
Patients in a DR screening 
program determined based on 
CFP to have Moderate+ DR 
OCT Device Heidelberg Spectralis Optovue iVue 
ci-DME Manual measurement of center 
point thickness >= 250um 
Automated measurement of 
central subfield thickness from 
Optovue’s software >= 300um 
Cases with Epimacular 
Membrane 
Excluded Not excluded 
Cases with macular edema from 
other causes 
Excluded Not excluded 
Cases with proliferative DR with 
neovascular membrane affecting 
the macula 
Excluded Not excluded 
Cases with previous laser 
treatment 
Excluded Not excluded 
 
Table S2:​ Comparison of the Thailand (training & primary validation) dataset and EyePACS-DME 
(secondary validation) dataset. 
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